Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00697931 | Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders | PHASE3 | COMPLETED | 116 | — | — | May 1, 1997 | Jun 1, 1998 | Jun 16, 2008 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Recombinant MPL- adjuvanted hepatitis B vaccine | BIOLOGICAL | Intramuscular injection, 3 doses |
| Engerix™-B | BIOLOGICAL | Intramuscular injection, 3 doses |
Inclusion Criteria: * Age: older than 18 years of age. * Documented non-responders 2 to 5 months after having received 4 doses of a hepatitis B vaccine * Good physical condition as established by clinical examination and history taking at the time of entry. * Female participants who are at risk to ...